187 related articles for article (PubMed ID: 22368266)
1. Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.
Müller P; Kazakov A; Semenov A; Jagoda P; Friedrich EB; Böhm M; Laufs U
J Cardiovasc Pharmacol Ther; 2013 Jan; 18(1):87-93. PubMed ID: 22368266
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.
Müller P; Kazakov A; Jagoda P; Semenov A; Böhm M; Laufs U
Cardiovasc Res; 2009 Jul; 83(1):106-14. PubMed ID: 19380417
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
4. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
5. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
6. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
8. Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.
Schmerbach K; Kalk P; Wengenmayer C; Lucht K; Unger T; Hocher B; Thoene-Reineke C
Clin Lab; 2012; 58(7-8):625-33. PubMed ID: 22997963
[TBL] [Abstract][Full Text] [Related]
9. Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
Anantharaman R; Bhansali A; Bhadada SK; Kohli HS; Dutta P; Walia R; Jayaprakash P; Upreti V
Indian J Med Res; 2010 Jul; 132():42-7. PubMed ID: 20693588
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Tao ZW; Huang YW; Xia Q; Xu QW
Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
[TBL] [Abstract][Full Text] [Related]
11. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
[TBL] [Abstract][Full Text] [Related]
12. Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells.
Müller P; Kazakov A; Semenov A; Böhm M; Laufs U
Cardiovasc Res; 2008 Jan; 77(1):151-9. PubMed ID: 18006457
[TBL] [Abstract][Full Text] [Related]
13. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
[TBL] [Abstract][Full Text] [Related]
14. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
16. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats.
Liang B; Leenen FH
J Cardiovasc Pharmacol; 2008 May; 51(5):457-66. PubMed ID: 18418273
[TBL] [Abstract][Full Text] [Related]
17. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
Liebson PR; Amsterdam EA
Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
[TBL] [Abstract][Full Text] [Related]
18. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
19. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
Petrovic I; Petrovic D; Vukovic N; Zivanovic B; Dragicevic J; Vasiljevic Z; Babic R
J Int Med Res; 2005; 33 Suppl 1():39A-49A. PubMed ID: 16222899
[TBL] [Abstract][Full Text] [Related]
20. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
